RedHill Biopharma has said it intends "to request a pre-NDA meeting with the FDA in the coming weeks to discuss a US NDA marketing approval application for RHB-102", its once-daily controlled release formulation of the antiemetic, ondansetron, for the prevention of nausea and vomiting in cancer patients.

GOGO reformulates Purell sanitizer; Life Extension brews up glucose support supplement; AllergEase allergy lozenges out in time for spring; Cardia 7 claims “heartier omega” mantle; extended-release SCOLR supplements debut; Tom’s of Maine rolls out natural antiperspirant; more New Products In Brief.

GOGO reformulates Purell sanitizer; Life Extension brews up glucose support supplement; AllergEase allergy lozenges out in time for spring; Cardia 7 claims “heartier omega” mantle; extended-release SCOLR supplements debut; Tom’s of Maine rolls out natural antiperspirant; more New Products In Brief.

Highlights from the Q2 2010 review of start-up dealmaking: Biopharma, medical device and in vitro diagnostics startups raised a total of $606 million, an 83% hike from the previous quarter but a 30% drop from Q2 2009. Unlike Q1, which saw four spin-offs, Q2 had just one. Three acquisitions closed including J&J's purchase of respiratory-focused RespiVert. During the second quarter of 2010, several companies signed multiple agreements including Clovis Oncology.